XML 75 R52.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
AstraZeneca |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Receivables from counterparty | $ 12 |  |
Payables to counterparty | 643 |  |
AstraZeneca | Total Sales |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Total Sales | 20 |  |
AstraZeneca | Materials and production costs |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 4 |  |
AstraZeneca | Marketing and administrative expenses |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 1 |  |
AstraZeneca | Research and development expenses |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 2,419 |  |
Bayer AG |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Receivables from counterparty | 33 | $ 0 |
Payables to counterparty | 352 | 353 |
Bayer AG | Total Sales |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Product sales, net | 149 | 88 | $ 0
Profit sharing | 151 | 81 | 30
Total Sales | 300 | 169 | 30
Bayer AG | Materials and production costs |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 99 | 133 | 67
Bayer AG | Marketing and administrative expenses |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 27 | 26 | 3
Bayer AG | Research and development expenses |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | $ 96 | $ 45 | $ 3

X
- Definition Collaborative Arrangement, Expenses + References No definition available. + Details
Name: | mrk_CollaborativeArrangementExpenses
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Payable + References No definition available. + Details
Name: | mrk_CollaborativeArrangementPayable
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Profit Sharing + References No definition available. + Details
Name: | mrk_CollaborativeArrangementProfitSharing
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Receivable + References No definition available. + Details
Name: | mrk_CollaborativeArrangementReceivable
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Revenues, Net of Commercialization Costs + References No definition available. + Details
Name: | mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Sales, Net + References No definition available. + Details
Name: | mrk_CollaborativeArrangementSalesNet
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mrk_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mrk_BayerAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |